Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077293 · ClinicalTrials.gov registry record
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 596
- Enrollment target
NCT05077293: Completed study, sponsored by NYU Langone Health.
NCT05077293 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 596 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05077293 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 596 participants
- Enrollment target
Study Summary
This is a feasibility study using a cross-over design to implement and compare a best practice alert (BPA) with an automated in-basket message to inform providers when a patient with heart failure and reduced ejection fraction (HFrEF) is not on appropriate medical therapy. The data from this pilot study will lead to a randomized controlled trial to compare the effectiveness of the BPA versus an automated in-basket message, versus usual care (no intervention).
Interventions
- OTHER Best Practice Alert (BPA)
- OTHER In-Basket Message
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2022-01-01 |
What the finished NCT05077293 record still lists
NCT05077293 is an observational study that tracks outcomes without assigning an intervention. The registered 596 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Best Practice Alert (BPA) is the first listed.
NCT05077293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05077293 about?
NCT05077293 is a clinical study titled "Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure". This is a feasibility study using a cross-over design to implement and compare a best practice alert (BPA) with an automated in-basket message to inform providers when a patient with heart failure and reduced ejection fraction (HFrEF) is not on appropriate medical therapy. The data from this pilot s...
What is the current status of trial NCT05077293?
This trial is currently completed. The enrollment target is 596 participants. The study started on 2021-09-09. Estimated completion is 2022-01-01.
What interventions are being tested in trial NCT05077293?
The interventions under investigation include: Best Practice Alert (BPA) (OTHER), In-Basket Message (OTHER).
Who is sponsoring clinical trial NCT05077293?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- NCT05723198 · 595 participants · Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI